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multifactorial process that needs a combination 
of genetic, environmental, and immune factors, 
has been accepted by most experts. However, the 
understanding of how the components are correlated 
with each other is still unclear. There is a possibility 
that those factors have roles as risk factors. They, 
combined with other factors, can cause the disease 
through mechanisms and pathways that are not yet 
fully understood.4,5
Synovial membrane in RA contains activated T 
cells and B cells, macrophages, and plasmocytes. 
It is also known that host tissue cells, such as 
synoviocytes, chondrocytes, and osteoclasts, are 
also involved in mediating bone and joint cartilage 
damages. Recruitment process, activation, and 
effectors of each contributors mentioned earlier are 
regulated through a network of cytokines.6–8
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Cytokines are protein secreted by cells implicated 
in adaptive and natural immunity that regulate 
various fundamental processes of the cells, such 
as infl ammation, tissue reparation, cell growth, 
fi brosis, angiogenesis, and immune response. 
To understand about the role of cytokines in 
RA, comprehensive analysis is needed. Tissue 
availability from pathogenic site (synovial joint) 
facilitates investigation and identifi cation of role of 
cytokines.9,10
In RA, cytokines secreted by those cells have 
important roles in causing infl ammation, articular 
destruction, and other comorbid diseases related 
to RA. Disease activity is also closely related to 
cytokines changes.5,6,11
Interleukin (IL)-1 and tumor necrosis factor 
α (TNFα) are major proinfl ammatory cytokines 
that have roles in infl ammation in RA; both have 
overlapping roles such as causing infl ammation, 
promoting infl ammatory cells’ adhesiveness, 
and causing angiogenesis and bone resoption. 
Tumor necrosis factor α is a cytokine secreted by 
macrophage and is the center of cytokines that 
have roles in pathogenesis of RA.5 Brennan et al6 
reported higher level of IL-1 in synovial culture 
of RA patients than that of osteoarthritis patients. 
Treatment with anti-TNFα monoclonal antibody 
can suppress IL-1 level. Further studies showed 
that suppression of TNFα also decreases other 
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Rheumatoid arthritis (RA) is a systemic autoimmune 
disorder indicated by chronic polyarthritis and 
synovitis that results in joint damage. It typically 
affects the peripheral synovial joints symmetrically. 
The clinical course of the disease is prolonged 
and accompanied by systemic complains.1,2 The 
manifestations are varied and early intensive 
management is needed to prevent joint damage and 
physical handicap.3  The disease had been described 
by Landre Beauvais since 1800 and the terminology 
of RA was fi rst introduced by Garrod in 1859.2
The etiology of RA is still unknown despite 
advances in the understanding of its pathogenesis. 
Several aspects that are also suspected of having 
roles in the pathogenesis of RA are as follows: 
(1) genetic factor or specifi c gene polymorphism; 
(2) pathogenic immune response and infectious 
agent-induced infl ammation; (3) autoimmunity 
toward synovium and cartilage components; (4) 
interference of regulation of proinfl ammatory 
cytokines production; and (5) transformation of 
constituent cells in the synovial into tissue invasive, 
autonomous cells.4
The perception that RA pathogenesis is a 
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cytokines production such as granulocyte macrophage colony-
stimulating factor (GM-CSF), IL-6, IL-8, and IL-9. It shows 
that there is a coordinated cytokine network in causing an 
infl ammation.5,6
There is an imbalance between proinfl ammatory and 
anti-infl ammatory cytokines, in which the proinfl ammatory 
ones are dominant. Raza et al12 reported that the level of 
proinfl ammatory cytokines produced by T cell, macrophage, 
and fi broblast, such as IL-2, IL-4, IL-13, IL-17, IL-15, basic 
fi broblast growth factor, and epidermal growth factor increase 
more evidently in RA patients as compared to non-RA arthritis 
patients.
Although the blocking of TNFα and IL-1 shows good 
response, there is still the possibility of failing to control the 
disease course of RA. It shows that there are other factors that 
also have roles, IL-17 for instance. Interleukin-17 is suspected 
of having role because fi rstly, it is similar to TNFα in its 
proinfl ammatory characteristic and secondly, it is produced by 
T cells, while the role of T cells is not yet fully understood.6,13
ROLE OF INTERLEUKIN-17 IN RHEUMATOID ARTHRITIS
Interleukin-17 is a cytokine produced by T cells. It was fi rst 
assumed as a product of Th1 cells, but then it was found that 
IL-17 is produced by Th17 cells which are similar to Th1 cells 
as derivation of CD4+ Th cells pathway. The differentiation 
into Th-17 cells is infl uenced by IL-23, IL-6, and IL-1B and it 
undergoes negative regulation infl uenced by IL-4, IL-10, and 
interferon γ (IFNγ).13–16 Interleukin-17 is a member of IL-17 
superfamily which consists of 6 members: IL-17A to IL-17F. 
Interleukin-17A is the strongest of them and is also known as 
IL-17. Interleukin-17 is a protein with a molecular weight of 17 
kDa and secreted in dimeric form with 155 amino acids.16,17
Interleukin-17 is a proinfl ammatory cytokine and has 
pleiotropic effects on various cells, including macrophages 
and fi broblasts, and is a strong candidate for effector cytokine 
contributing to the pathogenic condition of RA.18–20 Chabaud et 
al21 and Kohno et al22 measured IL-17 level of synovial tissue 
supernatant of RA patients, osteoarthritis patients, and healthy 
people. They found high level of IL-17 in RA patients, but not 
in osteoarthritis patients nor in healthy people. Shahrara et al23 
also found similar result. Higher levels of IL-17 in serum and 
in synovium of RA patients were also reported.15,18 A study by 
Chabaud et al21 showed that intra-articular injection of IL-17 to 
mice will induce joint cartilage degradation, while Jovanovic 
et al25 reported  treatment with IL-17 can initiate and maintain 
the infl ammatory response. 
Interleukin-17 is produced by cells of immune system 
that have roles in infl ammatory process in RA patients.13 It 
will stimulate the transcription activity of nuclear factor-B 
and IL-6 and the secretion of IL-8 by fi broblast, endothelial 
cells, and epithelial cells, and induce T cell proliferation.17,26 
Furthermore, IL-17 will stimulate synoviocytes to produce 
GM-CSF and prostaglandin E2, which means that IL-17 may 
have a role in promoting mediators in arthritis pathogenesis 
and functions as the controller of infl ammatory response.17,27 
Interleukin-17 will stimulate macrophages’ production of IL-
1 and TNF,25 support the production of IL-1–mediated IL-
6 by synoviocytes, and the synthesis of IL-1, IL-6, and IL-8 
induced by TNFα.17 It shows that IL-17 synergizes with TNF 
and IL-1, and the combination of those three will cause more 
tissue destruction.23,26
A study in mice showed the role of IL-17 in causing joint 
infl ammation. Interleukin-17–defi cient mice showed the 
important role of IL-17 in the activation of T cell-mediated 
immune responses. Interleukin-17–defi cient mice that were 
induced to have arthritis showed evident infl ammatory 
suppression, as well as prevention of the development of 
destructive arthritis in IL-1 receptor antagonist defi cient mice 
after inactivation of IL-17.17,28
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Figure 1   Effects of interleukin-17 on various cells implicated in 
rheumatoid arthritis. (Adapted from Miossec et al, 2003)3 
Interleukin-17 has double effects in joint cartilage, such 
as blocking the metabolism of chondrocytes in intact joint 
cartilage and inducing proteoglycan destruction. Matrix 
synthesis by chondrocytes is suppressed by increasing nitric 
oxyde production. Interleukin-17 also stimulates aggrecanase 
activity to degrade the matrix of joint cartilage.24,29 Cai et al29 
explained that the effect is independent of IL-1 and will be 
even greater if it synergizes with IL-1. Van Bezooijen et al30 
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also showed that IL-17 synergizes with TNFα to induce joint 
cartilage destruction. Meanwhile, Koshy et al31 stated that to 
stimulate release of metalloproteinase, IL-17 can work by 
itself or combined with proinfl ammatory cytokines produced 
by macrophage (IL-1 and TNFα).
Interleukin-17 is a cytokine of T cell which is potent in 
stimulating osteoclastogenesis. Interleukin-17, combined with 
TNFα, will increase osteoclastic resorption and the expression 
of receptor activator for nuclear factor-κB ligand (RANKL) in 
osteoblasts. RANKL is a regulator of osteoclastogenesis and 
can be blocked by osteoprotegerin (OPG).8,32 Lubberts et al17 
also found that in IL-17–defi cient mice, there was an obvious 
suppression of bone erosion if induced to be chronic arthritis. 









































is through loss of balance between RANKL and OPG.
In animal model, increase of IL-17 in joint with arthritis 
will cause infl ux of polymorphonuclear cells; thus, there will 
be a release of oxygen radical and proteolytic enzymes from 
those cells. This condition will aggravate the destruction of 
exposed joint.30 On the contrary, Yamada et al33 found that 
Th1, but not Th17 cells, predominate in the joints of patients 
with rheumatoid arthritis. In spite of that, murine studies using 
IL-17 inhibitor or anti–IL-17 monoclonal antibody showed 
promising results.34–36 In addition, a recent study by Genovese 
et al37 found that a humanized anti–IL-17 monoclonal 
antibody, added to oral disease-modifying antirheumatic drugs 
improved signs and symptoms of RA, with no strong adverse 
safety signal noted.
Figure 2   Role of interleukin-17 in the pathogenesis of rheumatoid arthritis. APC, antigen-presenting cell; IL, interleukin; TNFα, tumor 
necrosis factor α; RANKL, receptor activator for nuclear factor-κB ligand; MMP, matrix metalloproteinase.
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CONCLUSION
Rheumatoid arthritis is indicated by chronic infl ammation 
affecting connective tissues throughout the body, but it is 
mainly affecting diarthrodial joints. Roles of some cytokines 
are defi ned in the pathogenesis of RA. Other than the clear 
roles of TNFα and IL-1, there are many evidences that support 
the role of other cytokines; IL-17 is one of them. Several 
studies showed that this cytokine induces and maintains the 
infl ammation, especially in RA. Advances in the understanding 
of the role of IL-17 elicits the idea to modulate IL-17 and/or 
Th17 cells as the potential targets of therapy in RA.
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